USANA Health Sciences Reports Second Quarter 2026 Results
Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business
Key Financial Results
Second Quarter 2026 vs. Second Quarter 2025
-
Net sales of
$223 million $236 million -
Net loss of
$(21.4) million $29.1 million $9.7 million -
Diluted EPS of
$(1.16) $0.52 -
Adjusted diluted EPS(1) of
$(0.07) $0.74 -
Adjusted EBITDA(2) of
$27.8 million $30.5 million - Core Nutritional Active Customers of 384,000 versus 418,000.
- Hiya Active Monthly Subscribers of 166,000 versus 200,400.
- Company updates fiscal 2026 guidance.
Q2 2026 Consolidated Performance
|
Q2 2026 |
Year-Over-Year |
Sequentially |
Net Sales |
|
- |
- |
Net Loss* |
|
N/A |
N/A |
Diluted EPS |
|
N/A |
N/A |
Adjusted Diluted EPS(1) |
|
N/A |
N/A |
Adjusted EBITDA(2) |
|
- |
- |
*Income tax expense of |
|||
Net Loss, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of |
|||
“Our consolidated second quarter results reflect mixed performance as the Core Nutritional business delivered results generally in line with our expectations, while our ventures businesses performed below expectations,” said Kevin Guest, Chairman and Chief Executive Officer. “Specifically, Hiya continued to experience a challenging digital marketing environment, which pressured topline performance, subscriber growth, and margins. Additionally, Rise Wellness experienced a packaging-related disruption that impacted its commercial execution during the quarter. While we believe that these challenges for Hiya and Rise are temporary, and both companies remain well positioned to execute their growth strategies, we now expect net sales for these businesses during the full year to be below our prior expectations and are updating our outlook accordingly.
“We remain confident in USANA's strategic transformation from a single-channel direct sales business into a diversified, omnichannel health and wellness company built on consumer acquisition and loyalty. We are continuing to evolve our Brand Partner incentive plan, accelerate product innovation, and modernize our technology infrastructure. We remain confident that these initiatives will lead to long-term sustainable growth.
“Hiya’s talented management team continues to embrace the opportunity to leverage their brand across additional channels to reach a broader consumer base, while continuing to build on strong performance at a major national retailer, early-stage international expansion, and encouraging momentum in additional e-commerce channels. Rise Wellness’ high growth protein beverage brand, Protein Pop, is just a year old, and continues to attract new retailers, expand its presence with existing retailers and create the foundation for an exciting and expanded product pipeline. We recognize this progress will not always be linear quarter to quarter, and as we manage the business with that expectation in mind, our focus remains on building long-term loyalty from the consumers and Brand Partners who depend on our brands.”
Q2 2026 Segment Results
Core Nutritional
Core Nutritional |
|||
|
Q2 2026 |
Year-Over-Year |
Sequentially |
Net Sales |
|
- |
- |
Active Customers |
384,000 |
- |
- |
|
||||
|
Q2 2026 |
Year-Over-Year |
Year-Over-Year
|
Sequentially |
Net Sales |
|
- |
- |
- |
Active Customers |
307,000 |
- |
N/A |
- |
Asia Pacific Sub-Regions |
|||||
|
|
Q2 2026 |
Year-Over-Year |
Year-Over-Year
|
Sequentially |
|
Net Sales |
|
+ |
- |
- |
Active |
216,000 |
- |
N/A |
- |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
- |
Active |
32,000 |
- |
N/A |
Flat |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
- |
Active |
59,000 |
- |
N/A |
Flat |
|
Customers |
|||||
|
||||
|
Q2 2026 |
Year-Over-Year |
Year-Over-Year
|
Sequentially |
Net Sales |
|
- |
- |
- |
Active Customers |
77,000 |
- |
N/A |
- |
Hiya Health
|
Q2 2026 |
Year-Over-Year |
Sequentially |
Net Sales |
|
- |
- |
Active Monthly Subscribers |
166,000 |
- |
- |
Rise Wellness
|
Q2 2026 |
Year-Over-Year |
Sequentially |
Net Sales |
|
+ |
- |
Balance Sheet
The Company ended the quarter with
The Company did not repurchase any shares during the quarter and has approximately
Fiscal Year 2026 Outlook
The Company is updating its outlook for fiscal year 2026, as follows:
Fiscal Year 2026 Outlook |
||
|
Updated Estimate |
Previous Range |
Core Nutritional business net sales |
|
|
Hiya net sales |
|
|
Rise Wellness net sales |
|
|
Consolidated net sales |
|
|
|
|
|
Net (loss) earnings |
|
|
Diluted EPS |
|
|
Adjusted diluted EPS(1) |
|
|
Adjusted EBITDA(2) |
|
|
*Reflects an expected favorable currency exchange rate impact of approximately |
||
“Our GAAP net loss and negative Adjusted diluted EPS this quarter reflect lower-than-expected commercial performance from Hiya and Rise, and we’ve updated our full-year outlook accordingly,” said Doug Hekking, Chief Financial Officer. “Related to Hiya, we recorded an estimated preliminary non-cash goodwill impairment charge of
"Our balance sheet continues to be a source of strength, as we ended the period with
| _________________________ |
| (1) Adjusted Diluted (Loss) Earnings Per Share is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition-related intangible assets in calculating Adjusted Diluted (Loss) Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure. |
| (2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure. |
| (3) Estimated preliminary non-cash impairment charge was recognized, during the second quarter of 2026, to reduce goodwill, which impacted the Hiya reporting unit. |
Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted Diluted EPS. Adjusted EBITDA is a non-GAAP financial measure of (loss) earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net (loss) earnings. Adjusted Diluted EPS is a non-GAAP financial measure of diluted (loss) earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.
Adjusted EBITDA (non-GAAP) is net (loss) earnings (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.
Adjusted diluted (loss) earnings per share (non-GAAP) is diluted (loss) earnings per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses and integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.
Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted (loss) earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.
The Company prepares its financial statements using
Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands) |
||||||||
|
|
Quarter ended |
||||||
|
|
July 4,
|
|
June 28,
|
||||
Net (loss) earnings attributable to USANA (GAAP) |
|
$ |
(21,382 |
) |
|
$ |
9,655 |
|
Net (loss) earnings attributable to noncontrolling interest |
|
|
(6,569 |
) |
|
|
789 |
|
Net (loss) earnings |
|
$ |
(27,951 |
) |
|
$ |
10,444 |
|
|
|
|
|
|
||||
Adjustments: |
|
|
|
|
||||
Income taxes |
|
$ |
9,051 |
|
|
$ |
8,373 |
|
Interest (income) expense |
|
|
(595 |
) |
|
|
(360 |
) |
Depreciation and amortization |
|
|
4,714 |
|
|
|
5,148 |
|
Amortization of intangible assets - Hiya |
|
|
4,456 |
|
|
|
4,456 |
|
(Loss) earnings before interest, taxes, depreciation, and amortization (EBITDA) |
|
$ |
(10,325 |
) |
|
$ |
28,061 |
|
|
|
|
|
|
||||
Add EBITDA adjustments: |
|
|
|
|
||||
Non-cash share-based compensation |
|
|
3,404 |
|
|
|
3,622 |
|
Estimated preliminary impairment |
|
|
29,137 |
|
|
|
— |
|
Transaction, integration and transition costs - Hiya |
|
|
2 |
|
|
|
115 |
|
Inventory step-up - Hiya |
|
|
— |
|
|
|
544 |
|
Adjusted EBITDA |
|
|
22,218 |
|
|
|
32,342 |
|
Adjusted EBITDA attributable to noncontrolling interest |
|
|
5,629 |
|
|
|
(1,847 |
) |
Adjusted EBITDA attributable to USANA |
|
$ |
27,847 |
|
|
$ |
30,495 |
|
Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP) (in thousands, except per share data) |
||||||||
|
|
Quarter ended |
||||||
|
|
July 04,
|
|
June 28,
|
||||
Net (loss) earnings attributable to USANA (GAAP) |
|
$ |
(21,382 |
) |
|
$ |
9,655 |
|
|
|
|
|
|
||||
Earnings (loss) per common share - Diluted |
|
$ |
(1.16 |
) |
|
$ |
0.52 |
|
Weighted Average common shares outstanding - Diluted |
|
|
18,486 |
|
|
|
18,536 |
|
|
|
|
|
|
||||
Adjustment to net (loss) earnings: |
|
|
|
|
||||
Transaction, integration and transition costs - Hiya |
|
$ |
2 |
|
|
$ |
115 |
|
Inventory step-up - Hiya |
|
|
— |
|
|
|
544 |
|
Estimated preliminary impairment |
|
|
29,137 |
|
|
|
— |
|
Amortization of intangible assets - Hiya |
|
|
4,456 |
|
|
|
4,456 |
|
Adjustments to net (loss) earnings attributable to noncontrolling interest |
|
|
(7,106 |
) |
|
|
(1,057 |
) |
Income tax effect of adjustments to net (loss) earnings |
|
|
(6,346 |
) |
|
|
— |
|
Adjusted net (loss) earnings attributable to USANA |
|
$ |
(1,239 |
) |
|
$ |
13,713 |
|
|
|
|
|
|
||||
Adjusted (loss) earnings per common share - Diluted |
|
$ |
(0.07 |
) |
|
$ |
0.74 |
|
Weighted average common shares outstanding - Diluted |
|
|
18,486 |
|
|
|
18,536 |
|
Management Commentary Document and Conference Call
For further information on USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, August 5, 2026 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a question-and-answer session.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding commercial performance and growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2026 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya’s ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Hiya’s ability to perform in an expanding distribution channel and new international markets; risks related to Rise Wellness’ ability to execute its commercial plan and its dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts or such retailers discontinue purchasing and selling Rise Wellness products; risks related to governmental regulation of our products, manufacturing and direct selling business model in
About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers across 25 global markets. More information on USANA can be found at www.usana.com. USANA also owns a
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) |
|||||||
|
Three months ended |
||||||
|
July 4,
|
|
June 28,
|
||||
Net sales |
$ |
223,273 |
|
|
$ |
235,848 |
|
Cost of sales |
|
48,339 |
|
|
|
50,184 |
|
Gross profit |
|
174,934 |
|
|
|
185,664 |
|
Operating expenses: |
|
|
|
||||
Brand Partner incentives |
|
83,475 |
|
|
|
87,040 |
|
Selling, general and administrative |
|
82,318 |
|
|
|
81,906 |
|
Estimated preliminary impairment |
|
29,137 |
|
|
|
— |
|
Total operating expenses |
|
194,930 |
|
|
|
168,946 |
|
(Loss) earnings from operations |
|
(19,996 |
) |
|
|
16,718 |
|
Other income (expense): |
|
|
|
||||
Interest income |
|
595 |
|
|
|
619 |
|
Interest expense |
|
— |
|
|
|
(259 |
) |
Other, net |
|
501 |
|
|
|
1,739 |
|
Other income (expense), net |
|
1,096 |
|
|
|
2,099 |
|
(Loss) earnings before income taxes |
|
(18,900 |
) |
|
|
18,817 |
|
Income taxes |
|
9,051 |
|
|
|
8,373 |
|
Net (loss) earnings |
|
(27,951 |
) |
|
|
10,444 |
|
Net (loss) earnings attributable to redeemable noncontrolling interest |
|
(6,569 |
) |
|
|
789 |
|
Net (loss) earnings attributable to USANA |
$ |
(21,382 |
) |
|
$ |
9,655 |
|
|
|
|
|
||||
(Loss) earnings per common share attributable to USANA |
|
|
|
||||
Basic |
$ |
(1.16 |
) |
|
$ |
0.52 |
|
Diluted |
$ |
(1.16 |
) |
|
$ |
0.52 |
|
|
|
|
|
||||
Weighted average common shares outstanding |
|
|
|
||||
Basic |
|
18,486 |
|
|
|
18,513 |
|
Diluted |
|
18,486 |
|
|
|
18,536 |
|
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) |
|||||
|
As of
|
|
As of
|
||
ASSETS |
|
|
|
||
Current assets |
|
|
|
||
Cash and cash equivalents |
$ |
168,560 |
|
$ |
158,380 |
Trade accounts receivable (net of allowance of |
|
3,337 |
|
|
4,285 |
Inventories |
|
86,343 |
|
|
102,608 |
Prepaid expenses and other current assets |
|
22,826 |
|
|
23,132 |
Total current assets |
|
281,066 |
|
|
288,405 |
Property and equipment, net |
|
94,269 |
|
|
94,383 |
Goodwill |
|
109,141 |
|
|
137,962 |
Intangible assets, net |
|
124,615 |
|
|
133,151 |
Deferred tax assets |
|
29,539 |
|
|
27,209 |
Other assets* |
|
64,580 |
|
|
61,805 |
Total assets |
$ |
703,210 |
|
$ |
742,915 |
|
|
|
|
||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY |
|
|
|
||
Current liabilities |
|
|
|
||
Accounts payable |
$ |
15,431 |
|
$ |
17,263 |
Line of credit |
|
— |
|
|
14,000 |
Other current liabilities |
|
90,244 |
|
|
97,302 |
Total current liabilities |
|
105,675 |
|
|
128,565 |
Deferred tax liabilities |
|
4,662 |
|
|
4,892 |
Other long-term liabilities |
|
21,900 |
|
|
23,186 |
|
|
|
|
||
Redeemable noncontrolling interest |
|
44,667 |
|
|
53,168 |
|
|
|
|
||
Total stockholders' equity attributable to USANA |
|
526,306 |
|
|
533,104 |
Total liabilities, redeemable noncontrolling interest, and stockholders' equity |
$ |
703,210 |
|
$ |
742,915 |
*Includes noncurrent inventories of |
|||||
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES SALES BY REGION (in thousands) (unaudited) |
|||||||||||||||||||||||||
|
Quarter ended |
|
|
|
|
|
|
|
|
||||||||||||||||
|
July 4,
|
|
June 28,
|
|
Change from prior year |
|
Percent change |
|
Currency impact on sales |
|
Percent change excluding currency impact |
||||||||||||||
Core Nutritional: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
$ |
114,614 |
|
51.3 |
% |
|
$ |
113,171 |
|
48.0 |
% |
|
$ |
1,443 |
|
|
1.3 |
% |
|
$ |
5,230 |
|
|
(3.3 |
%) |
|
|
28,719 |
|
12.9 |
% |
|
|
32,887 |
|
13.9 |
% |
|
|
(4,168 |
) |
|
(12.7 |
%) |
|
|
776 |
|
|
(15.0 |
%) |
|
|
13,814 |
|
6.2 |
% |
|
|
17,166 |
|
7.3 |
% |
|
|
(3,352 |
) |
|
(19.5 |
%) |
|
|
(991 |
) |
|
(13.8 |
%) |
|
|
157,147 |
|
70.4 |
% |
|
|
163,224 |
|
69.2 |
% |
|
|
(6,077 |
) |
|
(3.7 |
%) |
|
|
5,015 |
|
|
(6.8 |
%) |
|
|
34,458 |
|
15.4 |
% |
|
|
36,264 |
|
15.4 |
% |
|
|
(1,806 |
) |
|
(5.0 |
%) |
|
|
632 |
|
|
(6.7 |
%) |
Core Nutritional total |
|
191,605 |
|
85.8 |
% |
|
|
199,488 |
|
84.6 |
% |
|
|
(7,883 |
) |
|
(4.0 |
%) |
|
|
5,647 |
|
|
(6.8 |
%) |
Hiya |
|
28,261 |
|
12.7 |
% |
|
|
33,931 |
|
14.4 |
% |
|
|
(5,670 |
) |
|
(16.7 |
%) |
|
|
— |
|
|
(16.7 |
%) |
Rise |
|
3,407 |
|
1.5 |
% |
|
|
2,429 |
|
1.0 |
% |
|
|
978 |
|
|
40.3 |
% |
|
|
— |
|
|
40.3 |
% |
Consolidated total |
$ |
223,273 |
|
100.0 |
% |
|
$ |
235,848 |
|
100.0 |
% |
|
$ |
(12,575 |
) |
|
(5.3 |
%) |
|
$ |
5,647 |
|
|
(7.7 |
%) |
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CORE NUTRITIONAL ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION (unaudited) |
||||||||||
Core Nutritional Active Brand Partners by Region(1) |
||||||||||
(unaudited) |
||||||||||
|
|
As of
|
|
As of
|
||||||
|
|
|
|
|
|
|
|
|
||
|
|
60,000 |
|
35.9 |
% |
|
64,000 |
|
37.2 |
% |
|
|
44,000 |
|
26.3 |
% |
|
45,000 |
|
26.2 |
% |
|
|
25,000 |
|
15.0 |
% |
|
26,000 |
|
15.1 |
% |
Asia Pacific Total |
|
129,000 |
|
77.2 |
% |
|
135,000 |
|
78.5 |
% |
|
|
|
|
|
|
|
|
|
||
|
|
38,000 |
|
22.8 |
% |
|
37,000 |
|
21.5 |
% |
|
|
167,000 |
|
100.0 |
% |
|
172,000 |
|
100.0 |
% |
Core Nutritional Active Preferred Customers by Region(2) |
||||||||||
(unaudited) |
||||||||||
|
|
As of
|
|
As of
|
||||||
|
|
|
|
|
|
|
|
|
||
|
|
156,000 |
|
71.9 |
% |
|
167,000 |
|
67.9 |
% |
|
|
15,000 |
|
6.9 |
% |
|
23,000 |
|
9.3 |
% |
|
|
7,000 |
|
3.2 |
% |
|
11,000 |
|
4.5 |
% |
Asia Pacific Total |
|
178,000 |
|
82.0 |
% |
|
201,000 |
|
81.7 |
% |
|
|
|
|
|
|
|
|
|
||
|
|
39,000 |
|
18.0 |
% |
|
45,000 |
|
18.3 |
% |
|
|
217,000 |
|
100.0 |
% |
|
246,000 |
|
100.0 |
% |
| _________________________ | ||
(1) |
Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale. | |
(2) |
Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. |
|
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES OPERATING RESULTS AS A PERCENTAGE OF NET SALES (unaudited) |
||||||||||||||||
|
|
Quarter ended |
||||||||||||||
|
|
July 4, 2026 |
|
June 28, 2025 |
||||||||||||
|
|
Core Nutritional |
|
Hiya |
|
Rise |
|
Consolidated |
|
Core Nutritional |
|
Hiya |
|
Rise |
|
Consolidated |
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brand Partner incentives |
|
|
|
—% |
|
— |
|
|
|
|
|
—% |
|
—% |
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated preliminary impairment |
|
—% |
|
|
|
—% |
|
|
|
—% |
|
—% |
|
—% |
|
—% |
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) earnings from operations |
|
|
|
(110.0)% |
|
(50.5)% |
|
(9.0)% |
|
|
|
|
|
(12.9)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets |
|
—% |
|
|
|
|
|
|
|
—% |
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20260804653227/en/
Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com
Media contact:
Sarah Searle
(801) 954-7626
media@usanainc.com
Source: USANA Health Sciences, Inc.